Tectonic Strategy

Tectonic Therapeutic is a clinical-stage biotechnology company dedicated to the discovery and development of therapeutic proteins and antibodies targeting G-protein coupled receptors (GPCRs). Utilizing its proprietary GEODe™ platform, the company aims to overcome traditional challenges in GPCR drug discovery, specifically targeting "undruggable" receptors with biologics rather than small molecules. Its lead candidate, TX45, is an Fc-relaxin fusion protein currently in Phase 2 clinical trials for Group 2 pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) and Group 3 pulmonary hypertension (PH-ILD). The company's pipeline also includes TX2100, a long-acting APJ antagonist for hereditary hemorrhagic telangiectasia (HHT), and programs for fibrosis. Headquartered in Watertown, Massachusetts, Tectonic became a public company in June 2024 following its merger with AVROBIO.